Contributions
Abstract: EP1524
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - MRI and PET
Aim: Cognitive impairment is a frequent clinical manifestation of multiple sclerosis. Several correlations with MRI structural biomarkers have been highlighted. Perception of cognitive concerns appears to be related to several factors other than formal assessment results. Generally, caregiver perception of cognitive function in MS shows a stronger correlation with assessment results than patient's perception. The aim of our study was to evaluate the relationship between brain volume and cognitive impairment perception by MS patients and their caregivers.
Methods: a group of MS patients and their caregiver was recruited. All MS patients underwent to brain MRI to estimate brain volumes using SIENAX and to neuropsychological assessment using BICAMS battery results. Perception of cognitive impairment was evaluated using the patients and caregivers versions of the MSNQ (Multiple Sclerosis Neuropsychological Questionnaire). Clinical and demographical variable of included patients were also recorded. Depression and anxiety were evaluated using, respectively, Beck Depression Inventory and Zung Anxiety Scale.
Results: 75 MS patients and their Caregivers were recruited. Demographic and clinical features: Mean Age (42.3, SD: 11.2), mean EDSS 2.5 (S.D:1.3) ; Female/Male: 53/22.
BICAMS results showed a stronger correlation with the caregivers (r:-0.46, p< 0.001) than patients perception (r:-0.25; p:0.021)Cortical grey matter volume showed a significant correlation with mean BICAMS results (r: 0.53, P:< 0.001), with caregivers perception (r: 0.64, p< 0.001) but not with patients perception. The difference between patients and caregiver MSNQ scores showed a relationship with cortical grey matter volume (linear regression, p: 0.001) also controlling for age, EDSS and BICAMS results.
Conclusion: In our study caregiver perception is more related to cognitive assessment results than patient perception. Furthermore, our results support the hypothesis that brain volume loss could play a role in alteration of self- judgment in MS patients and confirm the importance of the caregiver point of view in cognitive function evaluatio
Disclosure:
Fenu G: has received honoraria for speaking from Merck Serono, Biogen, Novartis.Frau J: serves on scientific advisory boards for Biogen and Genzyme, has received honoraria for speaking from Merck Serono, Genzyme, Biogen and Teva.
Coghe G: has received honoraria for speaking from Almirall Merck Serono, Biogen, Novartis.
Lorefice L has received honoraria for speaking from Merck Serono, Biogen, Novartis.
Marrosu MG has received honoraria for speaking and consultancy from Merck Serono, Biogen,, Genzyme, Roche, Bayer, Almirall.
Cocco E has received honoraria for speaking and consultancy from Merck Serono, Biogen,, Genzyme, Roche, Bayer, Almirall.
Fronza M, Arru M, Barracciu MA, Sechi V, Loi L, Contu F have nothing to disclose
Abstract: EP1524
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - MRI and PET
Aim: Cognitive impairment is a frequent clinical manifestation of multiple sclerosis. Several correlations with MRI structural biomarkers have been highlighted. Perception of cognitive concerns appears to be related to several factors other than formal assessment results. Generally, caregiver perception of cognitive function in MS shows a stronger correlation with assessment results than patient's perception. The aim of our study was to evaluate the relationship between brain volume and cognitive impairment perception by MS patients and their caregivers.
Methods: a group of MS patients and their caregiver was recruited. All MS patients underwent to brain MRI to estimate brain volumes using SIENAX and to neuropsychological assessment using BICAMS battery results. Perception of cognitive impairment was evaluated using the patients and caregivers versions of the MSNQ (Multiple Sclerosis Neuropsychological Questionnaire). Clinical and demographical variable of included patients were also recorded. Depression and anxiety were evaluated using, respectively, Beck Depression Inventory and Zung Anxiety Scale.
Results: 75 MS patients and their Caregivers were recruited. Demographic and clinical features: Mean Age (42.3, SD: 11.2), mean EDSS 2.5 (S.D:1.3) ; Female/Male: 53/22.
BICAMS results showed a stronger correlation with the caregivers (r:-0.46, p< 0.001) than patients perception (r:-0.25; p:0.021)Cortical grey matter volume showed a significant correlation with mean BICAMS results (r: 0.53, P:< 0.001), with caregivers perception (r: 0.64, p< 0.001) but not with patients perception. The difference between patients and caregiver MSNQ scores showed a relationship with cortical grey matter volume (linear regression, p: 0.001) also controlling for age, EDSS and BICAMS results.
Conclusion: In our study caregiver perception is more related to cognitive assessment results than patient perception. Furthermore, our results support the hypothesis that brain volume loss could play a role in alteration of self- judgment in MS patients and confirm the importance of the caregiver point of view in cognitive function evaluatio
Disclosure:
Fenu G: has received honoraria for speaking from Merck Serono, Biogen, Novartis.Frau J: serves on scientific advisory boards for Biogen and Genzyme, has received honoraria for speaking from Merck Serono, Genzyme, Biogen and Teva.
Coghe G: has received honoraria for speaking from Almirall Merck Serono, Biogen, Novartis.
Lorefice L has received honoraria for speaking from Merck Serono, Biogen, Novartis.
Marrosu MG has received honoraria for speaking and consultancy from Merck Serono, Biogen,, Genzyme, Roche, Bayer, Almirall.
Cocco E has received honoraria for speaking and consultancy from Merck Serono, Biogen,, Genzyme, Roche, Bayer, Almirall.
Fronza M, Arru M, Barracciu MA, Sechi V, Loi L, Contu F have nothing to disclose